15.28 +0.03 (0.20%)
After hours: 6:01PM EST
|Bid||15.28 x 800|
|Ask||19.94 x 1000|
|Day's Range||15.20 - 15.90|
|52 Week Range||14.33 - 21.48|
|Beta (3Y Monthly)||2.95|
|PE Ratio (TTM)||50.16|
|Earnings Date||Feb 18, 2019 - Feb 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.33|
Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO, OTC:AGEEF) is pleased to announce it has signed a letter of intent to enter into a partnership with Bophelo Bioscience and Wellness Pty Ltd (“Bophelo Bioscience”), a Lesotho based cannabis company. Halo will provide management services and expertise to build, design and operate cGAP cultivation and cGMP extraction facilities in exchange for a 20% equity position in Bophelo Bioscience, as well as a royalty on future extracted products. The Company has also entered into an off-take agreement whereby Halo will acquire all of Bophelo Bioscience’s production at prevailing market rates at time of production.
Halo Labs Inc. ("Halo" or the "Company") (HALO) is pleased to announced the start of production in Cathedral City, California commenced on November 28, 2018. The initial 1,600 square foot dedicated extraction facility is capable of producing approximately 120,000 grams of cannabis distillate per week. The Company expects to begin generating revenue from this facility by the first week of January 2019.
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") ...
Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. (“Halozyme” or the “Company”) (NASDAQ: HALO). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct.
NEW YORK , Nov. 29, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") (NASDAQ: HALO). Such ...
NEW YORK, Nov. 29, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Halozyme Therapeutics, Inc..
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Halozyme Therapeutics Inc (NASDAQ:HALO), with a market capitalization of US$2.2b, rarely draw their attention from the investing Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Wall Street closed up on Monday as oil prices stabilized and giant tech stocks such as the FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet), ...
-FDA Agrees to Company Request to Change Primary Endpoint to Overall Survival- -Previously Planned Interim Analysis Will Not Be Conducted- -Management to Host Webcast / Conference Call Today at 5 p.m. ...
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / U.S. equities regained footing on Thursday as oil prices climbed and hopes of a trade agreement between the U.S. and China raised investor’s optimism. The ...
Halo Labs Inc. ("Halo" or the "Company") (HALO) is pleased to report dispensary sales of approximately US$1.23 million for October 2018. Approximately US$245,000 of the dispensary sales in October was derived from the Company’s first full month of sales to dispensaries in Nevada. In the month of October 2018, Halo saw steady growth in dispensary sales of approximately US$1.0M in Oregon, up from US$855K in September 2018.
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 17.39% and -17.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of 19 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
- ENHANZE® Licensed to Roche for up to Three Additional Targets, Includes $25 Million Upfront Payment, Plus the Potential for Future Milestone and Royalty Payments - - 2018 Guidance Raised for Net Revenue ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO ) unveils its next round of earnings this Tuesday, Nov. 6. Get prepared with Benzinga's ultimate preview for Halozyme Therapeutics' Q3 earnings. Earnings and Revenue ...
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Albert Kildani has ...
Halo Labs Inc. ("Halo" or the "Company") (HALO) is pleased to announce it has launched its edibles line in Oregon, with the introduction of three edible products including single piece chews, a gummy ten pack and a syrup based drink. The Company has commenced sales of the gummy ten packs under the Drops™ brand, with Hush single piece chews and Hush Lean Back Syrup scheduled for release in stores by mid-November. The launch of edibles is a natural extension given Halo’s expertise in manufacturing high quality cannabis extracts and oils and provides the Company with exposure to the fastest growing sector in the cannabis industry with a higher margin profile than the existing Halo product line.